June 28, 2024 08:30 AM Eastern Daylight Time
Almirall’s Ilumetri® (tildrakizumab) Restores and Maintains Wellbeing of Patients With Moderate-to-severe Plaque Psoriasis to the Levels of the General Population for up to 1 Year1
View Full Size
Download
Full Size
JPEG, 751x329, 62.4 KB
Small
JPEG, 480x210, 38.3 KB
Preview
JPEG, 144x63, 6.8 KB
Thumbnail
JPEG, 120x53, 5.3 KB
Smart Multimedia Gallery
Share
Facebook
Twitter
LinkedIn
Delicious
Reddit
StumbleUpon
Digg
MySpace
Newsvine
Google Bookmark
Yahoo! Bookmark
Email
All News
|
News with Multimedia
>
Press Release: Almirall’s Ilumetri® (tildrakizumab) Restores a...
Get Business Wire News on Your Website
Terms of Use
|
© 2024 Business Wire